[ad_1]
Macleods Pharmaceuticals Limited recalls many tablets of the losartan potassium / hydrochlorothiazide combination, as they could contain a carcinogenic substance.
According to
US Food and Drug Administration website,
tablets, which treat hypertension and hypertensive patients with
left ventricular hypertrophy
, contained small amounts of N-nitrosodiethylamine (NDEA).
The recalled 100 mg / 25 mg tablets include:
NDC | Maker | Product Description | Lot / Lot | Expiration date | ||||
33342-0052-10 | Macleods Pharmaceuticals Limited | Losartan Potassium / Hydrochlorothiazide combination tablets 100 mg / 25 mg, bottles of 90 | BLM715A | July -1919 |
"Patients taking Losartan Potassium / Hydrochlorothiazide tablets, USP should continue to take their medications because the risk of harm to the patient's health may be higher if treatment is stopped immediately without further treatment," says the FDA.
Anyone with any general questions about the return of this product should contact Qualanex by email at the address
or call 888-280-2042, Monday to Friday, 7:00 am to 4:00 pm Pacific Standard Time.
To read the full press release,
click here.
window.fbAsyncInit = function() { FB.init({
appId : '471244696370916',
xfbml : true, version : 'v2.9' }); };
(function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "http://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
[ad_2]
Source link